UNSPSC 51273923: Bupivacaine/epinephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273923 Bupivacaine/epinephrine is a Commodity code, but the recent state and local solicitations tagged under it do not reflect purchases of local anesthetic injectables. Instead, the code shows activity in broader pharmaceutical and drug-response procurement—specifically naloxone products, generic multi-source pharmaceuticals, and over-the-counter products distributed through state and local health agencies. State and local governments are buying naloxone and drug deactivation systems for community health support, generic pharmaceuticals through cooperative purchasing vehicles, and exploring direct-to-manufacturer prescription programs to optimize pharmacy benefit management. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state and local facilities across multiple states including Oregon). The mix reflects both standalone county procurement and larger state-level or cooperative arrangements designed to serve multiple jurisdictions.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multistate reach extending to Oregon and other participating jurisdictions. Recent representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager arrangements; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract awards effective July 1, 2026. The code shows substantial pharmaceutical procurement activity but limited alignment between the nominal commodity scope (local anesthetic injectables) and actual buying patterns reflected in posted solicitations.